USFDA completes pre-approval inspection at Laurus Labs’ facility in Andhra Pradesh

29 Oct 2022 Evaluate

US Food and Drug Administration (USFDA) has completed a Pre-Approval Inspection (PAI) at Laurus Labs’ manufacturing facility at Unit-5, Parawada, Visakhapatnam, Andhra Pradesh. The inspection was conducted from October 24, 2022 to October 28, 2022. The company has been issued a Form 483 with one observation. The observation is procedural in nature. The company will address the observation within stipulated timelines.

Laurus Labs is a leading research and development driven pharmaceutical company in India. The company has grown consistently to become one of the leading manufacturers of APIs for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas.

Laurus Labs Share Price

1082.30 -18.55 (-1.69%)
09-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1729.95
Dr. Reddys Lab 1209.45
Cipla 1466.15
Zydus Lifesciences 894.95
Lupin 2181.45
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×